Trial Profile
A Phase I Multiple-Rising Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of MK-3118, Oral Glucan Synthase Inhibitor in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2014
Price :
$35
*
At a glance
- Drugs Ibrexafungerp (Primary)
- Indications Mycoses
- Focus Adverse reactions
- Sponsors Merck & Co
- 20 Oct 2014 New trial record